
WHEN IS A MOLE AT RISK FOR MELANOMA?

The ABCDEs help evaluate your mole for signs of melanoma.



When melanoma is detected early, the survival rate is 99%1

The DermTech Melanoma Test is an innovative, non-invasive testing option for patients with suspicious moles

- Utilizes the DermTech Smart Stickers™ to gently lift skin cells to test for genes associated with melanoma²
- Provides reliable results to your doctor, typically within 5 business days
- Rules out melanoma with over 99% reliability³⁻⁵
- Has been used to test more than 100,000 moles⁶
- Shown to detect nearly 5x more melanoma than visual assessment alone⁷

This test is a physician-ordered laboratory developed test (LDT) and is regulated under the Clinical Laboratory Improvement Amendments (CLIA). DermTech's laboratory is qualified to perform high complexity testing, developed and analytically validated the LDT in accordance with CLIA standards, and is also accredited by the College of American Pathologists and holds a New York State Dept. of Health permit The test is not reviewed or approved by the FDA. False positive and false negative results may occur. Samples of insufficient quantity or quality may not produce a result. Additional indications for use are set

References: 1. Cancer Facts & Figures 2021. American Cancer Society. Accessed March 3, 2022. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf 2. Yao Z, et al. J Drugs Dermatol. 2017;16(10):979-986. 3. Gerami P, et al. J Am Acad Dermatol. 2017;76(1):114-120. 4. Jackson S, et al. SKIN J Cutan Med. 2020;4(2):105-110. 5. Skelsey M, et al. SKIN J Cutan Med. 2021;5(5):512-523. 6. Data on File. DermTech, Inc. 7. Brouha B, et al. SKIN J Cutan Med. 2021;5(1):13-18.



